No Data
No Data
Fosun Attends CIIE for the Seventh Time - Guo Guangchang: Confident That China's High-Level Openness Is a Historical Opportunity
There May Be Some Bright Spots In Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Earnings
Shanghai Fosun Pharma Announces Drug Registration Acceptance
Fosun Pharma (02196): The pharmaceutical registration applications for Levofloxacin Injection and Acyclovir Injection have been accepted by the National Medical Products Administration.
Fosun Pharma (02196) announced that Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the 'Company'...
Express News | Shanghai Fosun Pharma - Drug Registration Applications of Levofloxacin Injection and Cytarabine Injection by Units Accepted by Nmpa
Fosun Pharma (600196.SH): A subsidiary holding company received acceptance of pharmaceutical registration application.
GraceUnion November 4th | Fosun Pharma (600196.SH) announced that its holding subsidiary Chongqing Yaoyou Pharmaceutical Co., Ltd.'s Levofloxacin Injection (referred to as "New Drug 1") and its holding subsidiary Gismei (Wuhan) Pharmaceutical Co., Ltd.'s Azacitidine Injection (referred to as "New Drug 2") have each had their pharmaceutical registration applications accepted by the National Medical Products Administration. Both New Drug 1 and New Drug 2 are chemical drugs independently developed by this group (i.e. the Company and its holding subsidiaries/units). New Drug 1 is intended for the following mild, moderate, and severe infections caused by sensitive bacteria: (1) Hospital-acquired pneumonia.
No Data
No Data